News about Drug Discovery & Development

Alembic Pharma Gets USFDA Nod for Ophthalmic Suspension With CGT Manufacturing Advantage

The product has been granted Competitive Generic Therapy (CGT) designation, making Alembic eligible for 180 days of market exclusivity in the USA once the product is launched. This exclusivity period provides a significant commercial advantage by limiting competition during initial marketing.

Drug Discovery & Development | 12/12/2025 | By Darshana

MMV Joins iiCON to Boost Infectious Disease Drug Research and Manufacturing Innovation

iiCON, led by the Liverpool School of Tropical Medicine (LSTM), is a global infectious disease R&D programme that unites industry, academic institutions, and clinical bodies to accelerate the development of treatments, diagnostics, and prevention technologies for infectious diseases. Its mission is to save and improve lives.

Drug Discovery & Development | 11/12/2025 | By Darshana

India Broadens Vaccine Partnership as BIRAC - CEPI Deal Extended to mAb Research

The Union Cabinet has approved the renewal and expansion of the strategic partnership between the Biotechnology Industry Research Assistance Council (BIRAC) and the Coalition for Epidemic Preparedness Innovations (CEPI).

Drug Discovery & Development | 07/12/2025 | By Darshana

AstraZeneca Unveils Broadest Haematology Data Set Yet at ASH 2025

AstraZeneca is advancing its ambition to transform haematology care with new data from its expanding pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from 6–9 December 2025.

Drug Discovery & Development | 05/12/2025 | By Darshana |  240

GSK Showcases New Advances in Blood Cancer Treatments

GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, reinforcing the potential of its therapies to redefine outcomes for patients with difficult-to-treat blood cancers.

Drug Discovery & Development | 03/12/2025 | By Darshana

JFCR, NEC and Taiho Partner on Whole-Genome Driven Cancer Vaccine Research

JFCR, NEC, and Taiho have launched a joint research initiative to develop novel cancer vaccines using whole-genome data. The project is part of AMED’s national programme on whole-genome analysis, supporting efforts to demonstrate its clinical utility and build systems that translate genomic insights into patient benefits.

Drug Discovery & Development | 01/12/2025 | By Dineshwori

Imugene and JW Therapeutics Collaborate to Advance onCARlytics and Carteyva Combination in Solid Tumours

Imugene and JW Therapeutics have partnered to explore a new combination for refractory solid tumours, pairing Imugene’s onCARlytics (CF33-CD19) oncolytic virus with JW’s CD19 CAR-T therapy, Carteyva. The collaboration will begin with pre-clinical studies and advance to a Phase 1 investigator-initiated trial in China targeting hard-to-treat cancers.

Drug Discovery & Development | 01/12/2025 | By Dineshwori

Zydus Pharma Secures USFDA Approval for Generic Hypertension Drug

Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration to market Telmisartan tablets, a generic version of a commonly prescribed blood pressure medication.

Drug Discovery & Development | 26/11/2025 | By Darshana |  110

Alkem Launches De Simone Formulation Probiotic DSS in India

Alkem Laboratories has introduced DSS, the original De Simone formulation probiotic blend, to the Indian market for restoring gut microbiota balance and managing a wide range of gastrointestinal conditions.

Drug Discovery & Development | 24/11/2025 | By Darshana |  143

HRV Pharma, MetroChem Form Multi-Year CDMO Alliance for High-Value API Development

HRV Global Life Sciences (HRV Pharma), India’s first integrated virtual API and pharmtech company, has entered into a multi-year CDMO partnership with MetroChem API, a leading player in API development and manufacturing.

Drug Discovery & Development | 19/11/2025 | By Darshana |  138